|
| |
Overview
Financial Highlight
HeadlinesBusiness Background Yong Tai Bhd, through its subsidiaries, is engaged in the development of residential and commercial properties. The group has two reportable segments: Property development and Dyeing. Property development segment includes the development of residential and commercial properties; Dyeing segment is engaged in manufacturing and dyeing of fabric and related products. The company derives most of its revenue from Property development segment.
  sujibaby Technical looks good for the bulls. https://klse.i3investor.com/blogs/sujibaby_yongtai/2021-06-11-story-h156616 11/06/2021 12:38 PM  MarketPlayer 11th JUNE 2021 – YTB Healthcare Sdn Bhd, a subsidiary of Yong Tai Bhd has today received the first batch of inactivated Covid-19 Vaccine. The Vaccine was developed by the Group’s strategic partner, Shenzhen Kangtai Biological Products Co., Ltd. (“SZKT”). The arrival of the Vaccine, which was witnessed by Y.B. Senator Jaziri Alkaf Abdillah Suffian and YTB’s Chief Executive Officer and Executive Director Datuk Wira Boo Kuang Loon. SZKT’s Vaccine has obtained the Emergency Use Authorisation (“EUA”) granted by the Government of China. SZKT has also commenced its vaccination programme in China, and has been used to vaccinate millions of China citizens since 1 June 2021. This Phase 3 clinical trial will enrol 3,000 subjects from Malaysia, and the subjects will receive the Vaccine in 2 doses 28 days apart. Yong Tai is the exclusive distributor for SZKT’s Vaccine with a period of 5 years (renewable) for no less than 20 million doses yearly. “This venture will create a strong income stream and contribute positively to the Group,” Datuk Wira Boo said. 11/06/2021 3:27 PM keatdash73 2021 年 6 月 11 日 – 永大集团子公司 YTB Healthcare Sdn Bhd 今天收到了第一批来自深圳康泰灭活新冠状病毒疫苗。该疫苗由集团的合作伙伴 - 深圳市康泰生物制品有限公司（“SZKT”）开发。 Y.B.参议员 Jaziri Alkaf Abdillah Suffian 和 永大集团首席执行长兼执行董事拿督威拉巫光伦先生到场接收疫苗。 深圳康泰疫苗已获得中国政府授予的紧急使用授权（“EUA”）。 而自 2021 年 6 月 1 日起，中国已经启动了深圳康泰疫苗接种计划，已经为数百万中国公民接种疫苗。 这项第 3 期临床试验将招募马来西亚的 3,000 名接种者，接种者将在 28 天内分两次接种疫苗。 永大集团是深圳康泰为期 5年的疫苗独家经销商，每年不少于2千万剂。 “这项合资企业将创造强劲的收入来源，并为集团做出积极贡献。 11/06/2021 4:00 PM thomaszum 今天這裡好不熱鬧，除了一些朋友和前輩予以肯定和勉勵外，相信某些資金盤也稍微坐不住了，今天內竟然湧入至少5位新IP，還是第一次發言的那種，力挺 YongTai．朋友這樣缺乏點誠意，YongTai確實有極大潛能的，但如果總是這些新 IP跳出來，反而會讓大家下降價格上漲的心理價位喔！ － MarketPlayer － paseuophon_2 － waterbro － frycafeinc － keatdash73 其實應該怎麼做呢？請容我與你分享． 一鼓作氣，再而衰，三而竭 解釋： 第一次擊鼓士氣會大大增加，第二次擊鼓士氣就會減弱了，第三次擊鼓就沒有士氣了。主要說的就是氣勢最初時最旺盛的道理。做事要一氣呵成，還要有信心和毅力，如果接二連三的斷斷續續，會給你造成負面影響的。 相關戰役： 長勺之戰 (公元前684年) 作品名稱： 《曹劌論戰》 這一次就狠狠的拉升吧！只有上漲到新的箱體區間，才是新一輪的清洗．格局放大些，RM1 ~ RM2才是你們的目標．在這裡糾結於一兩毛錢，何苦來哉！ 11/06/2021 4:20 PM keatdash73 谢谢 thomas 点名 ， 我不是什么股市资金盘， 小弟买了YTB 一阵子，看到价钱没什么上，我还亏，就上i3 看看大家什么看法。。。 我没其他想法， 注册账号只是希望散播一些好消息来贡献一点，希望可以推高股价。。。 如果弄巧反挫 ， 请见谅。。。 12/06/2021 10:43 AM thomaszum 一般上市企業發佈該企業的相關新聞時，是有著一定的程序和注意事項的． 舉例，發佈重大消息前，必須第一優先通知 BURSA，而不適合先刊登在報章媒體上．因為這程序一旦錯亂了，BURSA可能就會給電話或正式發文詢問，雖然沒什麼，但無形中給自己增加了些作業程序．(視乎發佈的新聞以及市場的波動決定調查的力度) 當然，一般消息或關係夠鐵，我們就另當別論． 我們來看看昨天「Yong Tai receives first batch of SZKT's vaccine, paves way to launch phase 3 clinical trial in Malaysia」這新聞的發佈時間節點： June 11, 2021 17:41 pm - theedgemarkets.com 發佈新聞 「Yong Tai receives first batch of SZKT's vaccine, paves way to launch phase 3 clinical trial in Malaysia」 June 11, 2021 18:06 pm - theedgemarkets.com 發佈新聞 「收到深圳康泰生物首批疫苗 永大將在大馬啟動第三期臨床試驗」- MarketPlayer 發佈英文版 11/06/2021 3:27 PM （15:27 pm） keatdash73 發佈中文版 11/06/2021 4:00 PM （16:00 pm） 在新聞發佈的時間節點上，MarketPlayer 和 keatdash73 兩位的時間都比 the edge markets 早，且在當下是沒有其他正式新聞被發佈出來的． 所以如果是我誤解了，請 keatdash73 予以包涵和見諒．畢竟你們的動作太快了，在正式新聞發佈前兩個小時就在論壇中發佈新聞稿，而上市公司的新聞發佈是有程序的．如果處理不當，是觸及 Bursa 的管控機制的灰色地帶的． 再次與您說聲抱歉，如果我誤解了． ------------------------------------------------------ 現在就只能像 ceelo87 所說的般, "剩下来的就看幕前和幕后的老板在不在意市场的见解和‘民调’"．或許這周末主力認真考慮後會決定與大家同一陣線的 12/06/2021 12:14 PM sonickid I may not able to predict share price. Many of you have no idea how long a phase 3 trial needed to take. I can tell you it won’t concluded within 6 months even for emergency approval. With 3 approved vaccines available in Malaysia, finding volunteers is super task now. 这项第 3 期临床试验将招募马来西亚的 3,000 名接种者，接种者将在 28 天内分两次接种疫苗。 Just think how long it will take to get 3000 volunteers? No need to believe me, just walk in to more retail pharmacy, I’m sure you able to get 1-2 pharmacists used to work with NPRA. 12/06/2021 1:04 PM sujibaby https://www.thestar.com.my/news/nation/2021/05/26/citf-registration-for-astrazeneca-vaccination-slots-now-closed 268,000 doses of AstraZeneca eaten up in less than 4 hours, even when the government was honest on the risk involved. @sonickid, Be vigilant, Covid19 vaccine is the highly sought after item in 2021. 12/06/2021 2:01 PM sonickid What I mean getting 3000 Guinea pig is not easy when there’re 3 approved vaccines available. 12/06/2021 6:10 PM waterbro really not easy to get 3000 voluntary, but i see its a good start to let private company going into Vaccine. 13/06/2021 1:07 AM frycafeinc https://www.reuters.com/article/us-health-coronavirus-vaccine-kangtai-idUSKBN2CV1F6 Kangtai Biological's COVID-19 vaccine gets emergency use approval in China By Reuters Staff BEIJING (Reuters) - China has given emergency use approval to a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products, the company said on Friday, adding a sixth shot to the country’s vaccination drive. China has already administered 366.9 million doses to people using five home-made products, three of which adopt a similar technology as the Kangtai shot, where inactivated coronavirus that cannot replicate in human cells is used to trigger an immune response. Kangtai did not say on Friday what sectors of China’s population its shot could be used in, when use would start or how long the approval will be effective. A clinical trial record in April said Kangtai aimed to start a Phase III clinical trial this month involving 28,000 participants aged 18 and above to evaluate the efficacy and safety of its two dose-based shot given 28 days apart. The record, published in the site ClinicalTrials.gov, which is maintained by a department under the National Institute of Health of the United States, did not specify where the trial will take place. China’s vaccine administration law allows emergency use “within certain scope and time limit” of vaccines during major health crises. A COVID-19 shot from a unit of Chongqing Zhifei Biological Products is also being used in the country under emergency clearance. Kangtai has also obtained exclusive right to develop and manufacture the vaccine developed by AstraZeneca and Oxford University in mainland China. Reporting by Roxanne Liu and Meg Shen; Editing by Frances Kerry 13/06/2021 1:19 AM waikeong179 Even China also approved Kangtai Biological's vaccine to be used, then very likely YT will be able to get a positive results! 13/06/2021 8:23 AM sonickid waikeong179 Even China also approved Kangtai Biological's vaccine to be used, then very likely YT will be able to get a positive results! ========== The issue is not the result as few already countries already approved. The concern is the 3000 volunteers, you only submit after compiling all 3000 vaccine trial data in Malaysia to NPRA. NPRA will take easily 3 months to access the data. All in all, it can take up to a year. Many trials failed not because of efficacy but not enough subject tested. 13/06/2021 11:25 AM aceofsmackkk i believe at this stage, 3000 trials would not be a problem, everyone just want to survive this pandemic, government vaccination process is very slow 13/06/2021 11:42 AM sonickid Don’t forget you’re not just getting any 3000. Gender, age group, health condition etc etc. 13/06/2021 11:58 AM  336699 Why the need to delay with another unnecessary trial when China has done that and already rolling out the Kangtai vaccines to its people, and probably sending them out to countries in need. In a time of emergency like this, some procedures should be bypassed to save lives. Today Hishamuddin just said that too 13/06/2021 3:02 PM sonickid So easy to say “unnecessary trial”? Imagine anything happened to Malaysian, I don’t know how many say unnecessarily trial one will F the government? Especially NPRA. Or because you bought some Yong Tai share and you say unnecessarily? 13/06/2021 4:43 PM 336699 sonickid, in fact even all WHO approved vaccines were for "emergency use" only. None have gone through the required human trial period as this pandemic have took too many lives. No denial that I've some YTB shares, but lives of families, friends & others were most important. I'd said the same for all other vaccines that could be procured asap & to be rolled out immediately to save lives & to prevent UNNECESSARY DEATHS. I believed the trials done in China were of utmost stringent and shall be recognized to save lives, time and resources 13/06/2021 6:54 PM waikeong179 Maybe the point here is if YT capable to get another vaccine into Malaysia, out from so many medical organisation, it somehow shows that YT may have good up space for it's expansion in medical industry. 13/06/2021 7:10 PM sujibaby Can YongTai's vaccine get its approval? YongTai (7066): Vaccine Distribution Prospects https://klse.i3investor.com/blogs/sujibaby_yongtai/2021-06-13-story-h1566195354-YongTai_7066_Vaccine_Distribution_Prospects.jsp 13/06/2021 7:41 PM thomaszum 看見大家在這個周末非常積極地進行疫苗的討論，這是一件很棒的事．那代表著我們都很關心 YongTai 的發展，關心YongTai 的疫苗發展項目是否能夠幫助他崛起，從此成為 RM1 以上的超級大戶呢？ 我們知道KCONVAC疫苗是滅活疫苗，也獲得中國政府批准緊急使用．那究竟什麼是滅活疫苗？相較於其他疫苗，滅活疫苗有著什麼競爭優勢？中國為何主打滅活疫苗（已經投入市場的就有4款滅活疫苗）？ 而KCONVAC疫苗在多款滅活疫苗中的表現究竟如何？是否有競爭力？以及究竟多快才能在馬來西亞啟動有條件市場授權（CMA），甚至EUA呢？ 或許大家可以參考看看我新寫的 Blog：YongTai Berhad (7066) vs Foresight of the vaccine market - Part 5． https://klse.i3investor.com/blogs/thomaszum/539579.jsp 在這疫情的發展下，從開發 Reusable Anti-Viral Fabric Mask 過渡到研讀疫苗的測試報告了．真是活到老，學到老． 慶幸對加密貨幣還有一點點認識，接下來寫加密貨幣時可以稍微輕鬆一些，不用研讀那麼多化學相關知識了． 13/06/2021 8:20 PM thomaszum 不管我們說一千，道一百．最後看的還是 YT 的投資團隊或資金團，如果他們還在糾結在一兩毛馬幣的小格局裡，那只能說大家還是看開點，已經投入的就當作儲蓄定存，設一個目標價，到了價位賣了就轉移戰場．還沒投入，也不想等的，就轉移到新的戰場去吧！ 因為如果操盤的團隊格局那麼小，何苦來哉呢．．． 你就算讓一群人來這唱＂好＂的，但股價沒有朝氣，那一切就都是虛的．就讓我們看看明天的收盤價格究竟會如何吧．．．．．． 13/06/2021 8:34 PM sonickid 336699, yes non of the vaccines had gone thru all requirements compared standard protocol. That’s why it was still under emergency used. For your information, China is not the good place for trial as not enough Covid cases. You don’t study the efficacy rate in a place where not enough Covid cases. And I’m not saying YT vaccine can’t get emergency approval, just it may face greater difficulty 13/06/2021 8:44 PM waterbro 康泰疫苖要在大馬獲得真正批準使用，不知還有多久。。。。。 但是看网上的介紹，在中國是可以開始替人民注射了的。 還是讓人看到希望的光芒。 根據新華社的報導----〉深圳康泰生物制品股份有限公司14日发布公告称，该公司研发的新型冠状病毒灭活疫苗已获批在中国紧急使用。 目前，公司已启动开展新型冠状病毒灭活疫苗III期临床试验相关工作。 据康泰生物介绍，这是广东省第1个获批紧急使用的新冠疫苗。康泰生物今年4月在耶鲁大学、冷泉港实验室、英国医学杂志联合运营的Medrxiv平台及《中华医学杂志》发表的相关研究论文显示，康泰生物新冠灭活疫苗Ⅰ、Ⅱ期临床试验中0-28天免疫程序疫苗组的活病毒中和抗体几何平均滴度（GMT）为131.7，为康复者血清中和抗体GMT49.7的2.65倍，并无3级及以上不良事件发生。 康泰生物表示，新冠灭活疫苗研发和产业化工作进展顺利，位于深圳市南山区的配套生产车间已经完成建设并全面投入生产。 13/06/2021 10:27 PM Palmoilsabah *RHB♦️Investment Bank Bhd* *CORPORATE NEWS* •*Property developer *Yong Tai Bhd* has announced that its subsidiary YTB Healthcare Sdn Bhd (YTBH) today received the first batch of an inactivated Covid-19 vaccine developed by China-based Shenzhen Kangtai Biological Products Co Ltd (SZKT). The arrival of the vaccine followed the National Pharmaceutical Regulatory Agency granting its approval for the Clinical Trial Import License (CTIL) on June 3. This also enables YTBH to roll out the phase 3 clinical trial in Malaysia. _*Disclaimer*:This message is for information purposes only. Reproduction or dissemination to third party is prohibited. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information nor shall it be construed as an offer/solicitation or recommendation to buy/sell any stocks . Investors should make their own informed decisions by consulting your own independent adviser(s) before investing. We accept no responsibility or liability for loss or damage that may arise from the reliance of this message. For the full information regarding the stocks mentioned herein please refer to the relevant websites._ 14/06/2021 9:30 AM karuvanan 大家是成年人，估计大家并不会100%资金全部放在永大， 我预算大家 max 20% 大约50k, 成本当他是0.32左右， 看见bintai & solution 也是疫苗概念股，疫苗都还没出就被炒上炒下，那种滋味不好受吧， 永大的特点是，只要价格炒上来，就有大户丢票，形成one day show的格局， 总括来说，永大全部的好消息已经出来了，但是股价不上，就是不上，你吹他不涨， 老实说，股票买了就买了，就算现在止损也区区那一点钱，我们就等着疫苗正式批准，到时候再说， 毕竟我们不缺那一点钱来开饭。。。。何必天天究竟一毛几分， 如果到时候股价没有冲破0.50，那么就当作我们只是花几十千，看穿一个企业的人品，一点也不贵。。 总结，等看好戏 14/06/2021 2:33 PM  | | ||||||||||||||||||||||||||||||||||||||||||||||||
